Map Pharmaceuticals names new board member
Mr Ward is currently senior vice president and president of the cardiovascular sector at Medtronic. In this role, Mr Ward is responsible for all worldwide operations of the
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.